Abiraterone acetate (Zytiga®) for the treatment of newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).
|NCPE Assessment Process||Complete|
|Rapid review commissioned||03/10/2018|
|Rapid review completed||15/11/2018|
|Rapid Review outcome||A full pharmacoeconomic assessment is recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.